TITLE:
A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients

CONDITION:
HIV Infections

INTERVENTION:
Tenofovir DF

SUMMARY:

      This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate
      (tenofovir DF).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 65 Years
Criteria:

        Inclusion Criteria

          -  HIV-1 RNA levels greater than or equal to 30,000 copies/mL

          -  CD4 count greater than or equal to 200 cells/mm3

          -  Serum creatinine <1.5 mg/dl

          -  Hepatic transaminases less than or equal to 2.5 times the upper limit of normal

          -  Total bilirubin less than or equal to 1.5 mg/dL

          -  Adequate hematologic function

          -  Serum amylase less than or equal to 1.5 times the upper limit of normal

          -  Serum phosphate greater than or equal to 2.2 mg/dL

          -  Not pregnant

        Exclusion Criteria

          -  Prior treatment with antiretroviral therapy

          -  Immunization within 30 days of study entry

          -  A new AIDS defining condition within 30 days of study entry

          -  Receiving nephrotoxic agents, probenecid, chemotherapeutic agents, corticosteroids,
             interleukin-2
      
